Compare GXO & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GXO | INDV |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.4B |
| IPO Year | 2021 | 2014 |
| Metric | GXO | INDV |
|---|---|---|
| Price | $48.45 | $38.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $67.91 | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 05-05-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | 0.03 | ★ 0.69 |
| Revenue | ★ $13,178,000,000.00 | $1,239,000,000.00 |
| Revenue This Year | $6.81 | N/A |
| Revenue Next Year | $5.95 | N/A |
| P/E Ratio | $1,615.67 | ★ $54.91 |
| Revenue Growth | ★ 12.55 | 4.29 |
| 52 Week Low | $45.40 | $13.45 |
| 52 Week High | $66.85 | $41.00 |
| Indicator | GXO | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 57.75 |
| Support Level | $48.58 | $35.36 |
| Resistance Level | $55.55 | $41.00 |
| Average True Range (ATR) | 1.39 | 1.30 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 24.16 | 88.77 |
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).